Figma Inc. Class A Common Stock vs Cassava Sciences Inc — how do they compare? Figma Inc. Class A Common Stock trades at $21.88 (market cap $11.45B), while Cassava Sciences Inc trades at $0.71 (market cap $35.34M). The key difference: Figma Inc. Class A Common Stock is far larger — about 324× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (251,946 versus 12,424,893). Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and Cassava Sciences Inc for 38 Days on average.
| FIG | FLNA | |
|---|---|---|
Market Cap | $11.45B | $35.34M |
Volume | 12,424,893 | 251,946 |
Sector | Technology | Health |
52-Week High | $63.82 | $4.64 |
52-Week Low | $16.84 | $0.68 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $9.85B | -$47.34M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite recent positive FDA news lifting a clinical hold on its epilepsy drug. The company shows improving quarterly EPS beats but remains unprofitable with negative cash flows. Analyst consensus is strongly bullish with 8 buy ratings versus 4 holds.
The outlook hinges on clinical progress—FDA clearance enables Phase 2a trials in 2027, a key catalyst. Risks include sustained cash burn and fiduciary concerns highlighted in recent news. Investors should weigh the high analyst optimism against fundamental weaknesses and regulatory execution risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →